Back to Peptides
CognitiveLow Risk

Selank

Also known as: TP-7

Half-life:
60 minutes

Administration Routes

intranasalsubcutaneous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Selank is believed to modulate the expression of GABA-A receptor subunits and increase BDNF levels, contributing to its anxiolytic and neuroprotective profile. It appears to regulate serotonin transporter gene expression and influence dopaminergic signalling. Unlike classical anxiolytics, it does not appear to produce tolerance or physical dependence in animal models.

Selank is a synthetic heptapeptide analogue of tuftsin. Developed in Russia alongside Semax, it is researched for its anxiolytic and nootropic properties without the sedative effects associated with benzodiazepines. It is commonly studied for stress reduction, anxiety management, and cognitive performance in high-demand environments.

Primary Research Areas

  • cognitive
  • recovery

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Providers Offering Selank